New Haven, May 24, 2026, 18:02 (EDT)
Precipio Inc. heads into the Memorial Day break under pressure, with its Nasdaq-listed shares ending Friday at $23.80, down 3.09% on the day and 8.60% over five trading days. The stock is still up 3.57% for the year, but the latest move was a clear fade after its mid-May earnings update.
That matters now because investors cannot trade the stock again until Tuesday. Nasdaq’s 2026 calendar shows U.S. equity and options markets closed on Monday, May 25, for Memorial Day, stretching the reaction window around Precipio’s results and recent management-option disclosures.
The move also came against a firmer market tape. The S&P 500 rose 0.4% on Friday, the Nasdaq Composite added 0.2%, and the Russell 2000 index of smaller companies gained 0.9%, leaving Precipio lagging both big-cap tech and small-cap peers before the long weekend.
Precipio is a thinly traded nano-cap, so the price action can look more violent than the news flow. Google Finance listed the company’s market capitalization — the stock market value of all shares outstanding — at about $42.54 million, with Friday volume of 21,060 shares and a 52-week range of $9.00 to $33.63.
The company’s first-quarter report gave investors something to work with, but not a clean story. Net sales rose 36% from a year earlier to $6.71 million, helped by a 42% rise in service revenue, while product revenue was nearly flat. Precipio said it processed 4,912 cases in the quarter, up 63%, but lower average pricing partly offset the benefit.
The profit line was less kind. Precipio reported adjusted EBITDA of negative $0.16 million, compared with positive $0.96 million in the fourth quarter; adjusted EBITDA is a non-GAAP measure that strips out interest, taxes, depreciation, amortization and certain other items to give a rough view of operating performance. The company blamed the swing on CMS reimbursement cuts, a delayed product shipment, new business-development hires and the absence of a one-time fourth-quarter benefit. CMS is the U.S. agency that sets Medicare payment rules. Chief Executive Ilan Danieli said the quarter showed “non-commercial fluctuations” and argued that underlying growth remained intact. GlobeNewswire
There was also a pay angle. Precipio said earlier this month that 2025 market-based options for some managers vested after the stock rose more than 400% from the grant price and passed a 10-day VWAP threshold of $30.30. VWAP, or volume-weighted average price, is an average price adjusted for how much stock trades at each level. Danieli called the structure an “alignment of management incentives,” while the company said its 2026 grants now carry a $40 stock-price target and produced an $800,000 non-cash stock-compensation charge in the first quarter. Precipio
The competitive backdrop is not gentle. Precipio sits in cancer diagnostics, but it trades at a fraction of the size of better-known listed names such as Guardant Health and NeoGenomics. Guardant’s latest market value was about $15.6 billion, while NeoGenomics was about $1.19 billion, giving both far more scale, liquidity and analyst visibility than Precipio.
There is a real “but” in the filing. Precipio’s 10-Q said there remains substantial doubt about its ability to continue as a going concern, a term auditors and companies use when future operations depend on meeting business plans or finding financing. The company reported an accumulated deficit of $104.2 million and working capital of $2.1 million at March 31; if delayed shipments do not convert, reimbursement pressure deepens, or average prices stay weak, the stock could keep trading more on funding risk than revenue growth. SEC
Tuesday’s open will be the next test. The bulls will look for buyers to treat the first-quarter softness as timing and for the stock to stabilize after the five-day pullback. The bears have an easier line: revenue growth is useful, but cash, margins and liquidity still decide how long the story gets.
